BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16897589)

  • 1. Efficacy of voriconazole in experimental Cryptococcus neoformans infection.
    Mavrogiorgos N; Zaragoza O; Casadevall A; Nosanchuk JD
    Mycopathologia; 2006 Aug; 162(2):111-4. PubMed ID: 16897589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
    Silva EG; Paula CR; de Assis Baroni F; Gambale W
    Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of fluconazole, voriconazole-resistant Cryptococcus neoformans isolated from and immunocompetent patient.
    Mandras N; Roana J; Tullio V; Allizond V; Banche G; Scalas D; Fucale G; Cuffini AM
    J Chemother; 2011 Dec; 23(6):379-80. PubMed ID: 22233828
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of endogenous cryptococcal endophthalmitis with voriconazole.
    Vela JI; Díaz-Cascajosa J; Sanchez F; Roselló N; Buil JA
    Can J Ophthalmol; 2009 Dec; 44(6):e61-2. PubMed ID: 20051999
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection.
    Serena C; Pastor FJ; Mariné M; Rodríguez MM; Guarro J
    J Antimicrob Chemother; 2007 Jul; 60(1):162-5. PubMed ID: 17483143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
    Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
    J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcoid-like reaction in Cryptococcus neoformans infection.
    Yano S; Kobayashi K; Ikeda T; Kadowaki T; Wakabayashi K; Kimura M; Ishikawa S; Adachi Y; Araki K; Nagaoka S
    BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22847562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.
    Calvo E; Pastor FJ; Rodríguez MM; Pujol I; Guarro J
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4074-7. PubMed ID: 20625150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.
    Silva EG; Paula CR; Dias AL; Chang MR; Ruiz Lda S; Gambale V; Prates RA; Ribeiro MS
    Mycopathologia; 2011 Apr; 171(4):261-6. PubMed ID: 20972836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
    Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation.
    Fujioka K; Nagai T; Kinoshita Y; Urushihara M; Hamasaki Y; Shishido S; Kagami S
    CEN Case Rep; 2019 Nov; 8(4):261-265. PubMed ID: 31161376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulatory effect of voriconazole on the production of proinflammatory cytokines in experimental cryptococcosis in mice with severe combined immunodeficiency.
    Gonçalves Silva E; Marilia de Souza Silva S; Rodrigues Paula C; da Silva Ruiz L; Latercia Tranches Dias A
    J Mycol Med; 2018 Mar; 28(1):106-111. PubMed ID: 29273275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
    Friese G; Discher T; Füssle R; Schmalreck A; Lohmeyer J
    AIDS; 2001 Nov; 15(17):2344-5. PubMed ID: 11698718
    [No Abstract]   [Full Text] [Related]  

  • 15. New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans
    Lu RY; Ni TJ; Wu J; Yan L; Lv QZ; Li LP; Zhang DZ; Jiang YY
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
    Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
    J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.
    Sionov E; Chang YC; Garraffo HM; Dolan MA; Ghannoum MA; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1162-9. PubMed ID: 22155829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
    Chandrasekar PH; Cutright J; Manavathu E
    J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal activity of D0870 against murine infections and its mechanism of action.
    Yamada H; Tsuda T; Watanabe T; Kusakabe S; Mochizuki H
    Chemotherapy; 1998; 44(2):112-20. PubMed ID: 9551242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.
    Troke PF; Andrews RJ; Marriott MS; Richardson K
    J Antimicrob Chemother; 1987 May; 19(5):663-70. PubMed ID: 3038824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.